Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple myeloma (MM). Prof. McCarthy highlights measurable residual disease and covers the different techniques that can be used to determine this. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.